Abstract: Viral vectors are provided for use as genetic immunotherapeutic agents, including preventive and therapeutic vaccines as well as compositions to enhance cellular immune responses and innate immune responses. The vectors are particularly useful for treating or preventing cancer and infectious diseases. The vectors include lentiviral vectors that encode one or more antigens, a combination of adjuvants, and optionally may encode one or more soluble and secreted checkpoint inhibitor molecules. The adjuvants include latent membrane protein 1 (LMP1) from Epstein Barr virus and a fusion protein including LMP1 with in which the intracytoplasmic domain has been replaced by human IPS1 or a variant thereof capable of activating the STING pathway. The vector-encoded sequences are codon optimized for human expression.

Abstract: Promoter sequences for use in expressing a transgene in CD3+ cells are provided. The promoter sequences can be inserted into a vector in a 5? untranslated region proximal to a transgene. The promoters are selective for expression in CD3+ cells and contain binding sites for transcription factors found in CD3+ cells. The promoters can be integrated into vectors, including polymer-encapsulated lentiviral vector nanoparticles, used to transduce T-cells for genetic immunotherapy to treat cancer and infectious diseases. The T-cell selectivity of the promoters adds an improved safety factor to the use of viral vectors for immunotherapy in vitro and in vivo.

Abstract: Viral vectors are provided for use as genetic immunotherapeutic agents, including preventive and therapeutic vaccines as well as compositions to enhance cellular immune responses. The vectors are particularly useful for treating or preventing cancer and infectious diseases. The vectors include lentiviral vectors that encode one or more antigens and an adjuvant, and optionally may encode one or more soluble checkpoint inhibitor molecules. The adjuvant is a fusion protein including latent membrane protein 1 (LMP1) from Epstein Barr virus with in which the intracytoplasmic domain has been replaced by human IPS1 or a variant thereof capable of activating the STING pathway. The vector-encoded sequences are codon optimized for human expression.

Abstract: Engineered multispecific antigen binding molecules are provided which contain two or more different aptamer moieties joined by a linker. The antigen binding molecules are capable of specifically binding to one or more antigens and bridging different cell types, such as immune cells and cancer cells. The linked aptamers can be used to modulate and enhance immune function.

Abstract: Polymer-encapsulated viral vector nanoparticles and methods of using them provide enhanced delivery of genetic material for use in gene therapy and other applications. The nanoparticles include an outer shell containing an oligopeptide-modified poly(beta-amino ester) polymer which encapsulates the vector and allows the vector to transduce cells without the need for pseudotyping or the inclusion of any viral fusion protein, such as VSV-G. The polymer-encapsulated vector nanoparticles have a natural tropism for peripheral blood cells, such as leucocytes, without the need for a targeting moiety, and have an improved safety profile compared to pseudotyped viral vectors.

Abstract: Methods for synthesizing and purifying oligopeptide-modified poly-beta-amino-esters (OM-PBAEs) and related polymers without using DMSO as a solvent yield OM-PBAEs with improved storage stability in biocompatible buffers. The polymers can be stored for extended periods and used to encapsulate nucleic acids and viral vectors losing transfection or transduction efficiency.

Abstract: High affinity aptamer sequences recognizing CD3 protein complex on cell surfaces are provided. The aptamers can be used as targeting moieties for delivery vehicles or as molecular components for immunotherapy, immunodiagnostics, or for isolating, purifying, or characterizing CD3+ T cells in a subject.

Abstract: An aptamer-based switch technology is provided that enhances control of the use of chimeric antigen receptor (CAR)-related immunotherapies. The aptamer-based switch utilizes a synthetic bridge molecule containing a target-binding aptamer bound through a linker to a CAR-binding aptamer. A system containing a CAR and a corresponding aptameric bridge provides an immunotherapy platform that: (i) can be targeted to any desired antigen by choosing the target-binding aptamer of the bridge, (ii) can be redirected from one target to another by changing the target-binding aptamer; (iii) can be dosed according to the changing needs of an individual patient overtime by altering the administration protocol for the bridge; (iv) can be switched on or off quickly or gradually; (v) can be used as a companion diagnostic for a specific CAR therapy; (vi) can be integrated with either in vivo or ex vivo CAR expression; (vii) is non-immunogenic; and (viii) has low production costs.

Abstract: The present technology relates to gene delivery vehicles comprising a retroviral vector coated with a polymer or a mixture of polymers to form a nanoparticle. The retroviral vectors comprise a transgene and in certain embodiments lack envelope protein. The technology includes a method of making the gene delivery vehicles and a method of treating a disease by administering the gene delivery vehicles.

Abstract: Viral vectors are provided for use as genetic immunotherapeutic agents, including preventive and therapeutic vaccines as well as compositions to enhance cellular immune responses and innate immune responses. The vectors are particularly useful for treating or preventing cancer and infectious diseases. The vectors include lentiviral vectors that encode one or more antigens, a combination of adjuvants, and optionally may encode one or more soluble and secreted checkpoint inhibitor molecules. The adjuvants include latent membrane protein 1 (LMP1) from Epstein Barr virus and a fusion protein including LMP1 with in which the intracytoplasmic domain has been replaced by human IPS1 or a variant thereof capable of activating the STING pathway. The vector-encoded sequences are codon optimized for human expression.

Abstract: Methods of making lyophilized lentiviral vector particles are provided. Compositions comprising lyophilized lentiviral vector particles are also provided. Methods of administering a lentiviral vector particle to a subject and uses of lentiviral vector particle compositions are also provided.

Abstract: Viral vectors are provided for use as genetic immunotherapeutic agents, including preventive and therapeutic vaccines as well as compositions to enhance cellular immune responses. The vectors are particularly useful for treating or preventing cancer and infectious diseases. The vectors include lentiviral vectors that encode one or more antigens and an adjuvant, and optionally may encode one or more soluble checkpoint inhibitor molecules. The adjuvant is a fusion protein including latent membrane protein 1 (LMP1) from Epstein Barr virus with in which the intracytoplasmic domain has been replaced by human IPS1 or a variant thereof capable of activating the STING pathway. The vector-encoded sequences are codon optimized for human expression.

Abstract: A process for manufacturing an individual packaging for a liquid or solid product includes uninterruptedly unwinding a lower film while simultaneously unwinding an upper film with regard to the lower film. The process further includes continuously dispensing, between the two films, the product which is to be packaged and simultaneously forming and sealing the contour of each packaging by ultrasonic welding. This welding is carried out so that the ultrasound ejects the product from the zones being welded.

Abstract: A method and device for determining whether a product is in condition to be used or consumed, this product being intended to be preserved under temperature conditions and for a period of time which limit its degradation includes an indicator combined with the product, to provide a signal indicating that the product can be used or consumed, and then, after the expiration of a preservation period of time, a signal indicating a change in the condition of possible use or consumption of the product. The period of time depends on the preservation conditions of the product. The indicator provides information enabling the product to be used or consumed for a longer period of time if the product has been preserved under conditions better than recommended conditions or for a shorter period of time if the product has been preserved under conditions worse than recommended conditions.

Abstract: The invention pertains to a method, a system and a component for systematically and automatically controlling a product, whose preservation in a distribution circuit depends on temperature, in particular a product subjected to a cold chain. The method includes: affixing, on the product, a marker including elements, in particular the bars of a bar code, intended to be identified by automatic processing units, fixing a component on the product. The component includes at least one part including a mask intended for masking the elements of the marker, at least temporarily, without modifying them, when (i) the temperature of the product exceeds a specific temperature threshold or (ii) when the preservation conditions differ from a specific reference level, in particular characterized by the exceeding of a specific temperature threshold for a longer duration than a specific duration or by the exceeding of a specific preservation duration.

Abstract: An individual packaging method for a liquid or solid product, includes uninterruptedly unwinding a first film, or lower film, simultaneously unwinding a second film, or upper film, with regard to the lower film, continuously dispensing, between the two films, the product which has to be packaged, and simultaneously forming and sealing the contour of each packaging by means of ultrasonic welding, this welding being carried out so that the ultrasounds eject the product from the zones which are to be welded.

Abstract: The invention relates to device (10) for monitoring the degradation of a perishable product, this device being designed to be placed in the proximity of the product, this device comprising: A time measuring module (12), such as a clock, and at least one sensor (14) measuring at least one extrinsic variable of the product representing the preservation conditions of this product, such as the temperature, the relative humidity, the atmospheric composition. a programme memory (16) for memorising a programme representing a specific degradation model of a monitored product, a processor (18), using the programme representing the degradation model to calculate the condition of degradation of the product according to the time and values of the extrinsic variables measured by the sensor.

Abstract: A method and device for determining whether a product is in condition to be used or consumed, this product being intended to be preserved under temperature conditions and for a period of time which limit its degradation includes an indicator combined with the product, to provide a signal indicating that the product can be used or consumed, and then, after the expiration of a preservation period of time, a signal indicating a change in the condition of possible use or consumption of the product. The period of time depends on the preservation conditions of the product. The indicator provides information enabling the product to be used or consumed for a longer period of time if the product has been preserved under conditions better than recommended conditions or for a shorter period of time if the product has been preserved under conditions worse than recommended conditions.

Abstract: The invention pertains to a method, a system and a component for systematically and automatically controlling a product, whose preservation in a distribution circuit depends on temperature, in particular a product subjected to a cold chain. The method includes: affixing, on the product, a marker including elements, in particular the bars of a bar code, intended to be identified by automatic processing units, fixing a component on the product. The component includes at least one part including mask intended for masking the elements of the marker, at least temporarily, without modifying them, when (i) the temperature of the product exceeds a specific temperature threshold or (ii) when the preservation conditions differ from a specific reference level, in particular characterized by the exceeding of a specific temperature threshold for a longer duration than a specific duration or by the exceeding of a specific preservation duration.